Culture Biosciences Valuation, Funding & Investors
Culture Biosciences is valued at $220M as of October 2021.
Last Culture Biosciences valuation
$220M
Series B · Oct 2021
Last Culture Biosciences funding round
Series C
Amount undisclosed · Dec 2025
Cumulative funding Culture Biosciences raised
$101M
across 5 funding rounds
Key investors in Culture Biosciences
S32
Cultivian Sandbox Ventures
Verily
Y Combinator
BoxGroup
Craft Ventures
About Culture Biosciences
Culture Biosciences is a San Francisco-headquartered biotech firm offering a cloud-connected biomanufacturing platform with robotic bioreactors. Its system enables parallel experimentation for process development in fermentation and cell culture, serving pharmaceutical and industrial biotech clients. Founded in 2016, the company has raised over $100 million in funding and operates a 20,000-square-foot facility in South San Francisco for high-throughput runs.
Founded
2016
HQ
San Francisco, CAWebsite
Status
Privately held
Customer focus
B2B
Revenue model
Usage-based, Subscription
Valuation
$220M (Oct 2021)
Culture Biosciences Valuation
Culture Biosciences is currently valued at $220M, based on its Series B in October 2021.
The $80M round was led by Northpond Ventures, with participation from GRIDS Capital, Verily, E14 Fund, Synthesis Capital, BoxGroup and 5 other investors.
Culture Biosciences valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Oct 2021 | Series B | $220M |
Culture Biosciences Funding History
Culture Biosciences has raised a total of $101M across 5 funding rounds.
Culture Biosciences' first fundraising round was a $100K seed round in January 2018. The most recent completed round was a Series C in December 2025.
Culture Biosciences funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Dec 2025 | Series C | Cultivian Sandbox Ventures (lead); Northpond Ventures (lead); S32 (lead); Synthesis Capital (lead) | - | - | Culture Biosciences, a leader in cloud-based biomanufacturing based in South San Francisco, CA, closed its Series C funding round on December 16, 2025, led by existing investors Northpond Ventures, Synthesis Capital, S32, and Cultivian Sandbox Ventures. The round will accelerate commercial expansion of the company's next-generation hardware product, the Stratyx 250, which provides scalable, automated, and digitally connected bioprocess capacity for biologics, cell therapy, and advanced bioprocess development. It will also fund continued development of Culture's AI-powered Console software ecosystem. Culture Biosciences offers a cloud bioreactor platform that enables bioprocess scientists to design experiments executed in 250mL bioreactors, with real-time monitoring, data analysis, and advanced visualization tools to accelerate bioprocess development. The company helps customers in biopharma and synthetic biology unify high-throughput experimentation with data-driven process design. |
| Oct 2021 | Series B | Northpond Ventures (lead); GRIDS Capital; Verily; E14 Fund; Synthesis Capital; BoxGroup; Cultivian Sandbox Ventures; S32; The Production Board (TPB); Team Builder Ventures; Craft Ventures | $80M | $220M | Culture Biosciences operates cloud-based bioreactor labs that enable biotech companies to develop and scale biomanufacturing processes remotely, addressing capacity gaps in synthetic biology and biopharma for products like food, clothing, and vaccines. The company announced an $80 million Series B funding round on October 14, 2021, led by Northpond Ventures with participation from Synthesis Capital, Cultivian Sandbox Ventures, The Production Board, Craft Ventures, E14 Fund, BoxGroup, Verily Life Sciences, and Section 32, among others matching the query's investor list. This brought total funding raised to over $100 million following a $15 million Series A in 2020. By late 2021, Culture had achieved 3x year-over-year growth since the Series A, serving over 30 leading biotech firms, launching the Culture Cloud Console for data analysis and collaboration, expanding to mammalian cell culture and analytical chemistry, and doubling its employee count. The funding supports building 5L and 250L cloud bioreactors for pilot-scale production to meet customer needs for larger material quantities in testing and regulatory approvals, aiming to digitize biomanufacturing R&D from bench to pilot. The round reflects surging demand for bio-based products amid infrastructure shortages, with Northpond Ventures highlighting Culture's role in scaling beyond bench optimization. A 2020 company survey indicated pilot-scale bioreactors as the most valued offering among biopharma and synbio firms. |
| Mar 2020 | Series A | Cultivian Sandbox Ventures (lead); Verily; E14 Fund; Y Combinator; S32; The Production Board (TPB); Sandbox Industries; DCVC; Craft Ventures | $15M | - | Culture Biosciences, based in South San Francisco, California, provides biomanufacturing research and development services through a cloud bioreactor platform that enables real-time monitoring, control, data visualization, and analytics for bioprocesses in fermentation and mammalian cell culture. The platform helps companies scale lab discoveries to commercial production faster by automating bioreactor operations and generating insights into bioprocesses. By April 2020, the company had acquired more than 30 customers ranging from startups to large firms and expanded its infrastructure. On March 4, 2020, Culture Biosciences raised $15 million in a Series A funding round led by Cultivian Sandbox Ventures, with participation from The Production Board, Verily Life Sciences, Section 32, Y Combinator, and E14 Fund. This followed a $5.5 million seed round in February 2019 led by Section 32 with Verily and Refactor Capital. The Series A proceeds supported tripling bioreactor capacity from 80 to over 300 units, development of digital manufacturing tools, and maintaining a capital-light model by building lower-cost reactors in-house. Cultivian Sandbox managing director Dan Phillips and The Production Board founder David Friedberg joined the board. |
| Feb 2019 | Series A | S32 (lead); Uncommon Denominator; Verily; Steven Lurie; Refactor; Ben Davenport; Michael Dempsey | $6M | - | Culture Biosciences completed a Seed VC - II funding round on February 12, 2019, raising $5.5 million led by Section 32, with participation from Refactor Capital and Verily. The company is a South San Francisco-based biotech firm providing cloud-based biomanufacturing infrastructure, allowing customers to design and manage high-throughput fermentation experiments remotely. At the time of the round, Culture operated approximately 150 bioreactors and positioned its platform as a solution to accelerate the development and scale-up of biologics, cell therapy, and bioprocess development by replacing legacy fermentation approaches. The company's value proposition addressed the bottleneck in scale-up processes that traditionally required companies to either build in-house fermentation facilities or contract outside labs, both of which limited speed, flexibility, and convenience while extending lab-to-market timelines. |
| Jan 2018 | Seed | Y Combinator (lead); Compound; Liquid 2 Ventures; BoxGroup; Jonathan Downey; UpHonest Capital | $100K | - | - |
Who has invested in Culture Biosciences?
23 investors have backed Culture Biosciences across its funding rounds, including S32, Cultivian Sandbox Ventures, Verily, Y Combinator, BoxGroup and Craft Ventures.
Lead investors include Cultivian Sandbox Ventures, Northpond Ventures, S32, Synthesis Capital and Y Combinator.
Culture Biosciences Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| San Diego, CA | 4 | Lead | Feb 2019 | |
| San Francisco, CA | 3 | Participant | Feb 2019 | |
| Chicago, IL | 3 | Lead | Mar 2020 | |
| Washington, DC | 2 | Lead | Oct 2021 | |
| United States | 2 | Participant | Mar 2020 | |
 London | 2 | Lead | Oct 2021 | |
| San Francisco, CA | 2 | Lead | Jan 2018 | |
| New York City, NY | 2 | Participant | Jan 2018 | |
| San Francisco, CA | 2 | Participant | Mar 2020 | |
| San Francisco, CA | 2 | Participant | Mar 2020 | |
 São Paulo | 1 | Participant | Oct 2021 | |
| New York City, NY | 1 | Participant | Jan 2018 | |
| New York City, NY | 1 | Participant | Feb 2019 | |
This data is available for Pro users. Sign up to see all 23 Culture Biosciences investors. Start Free Trial | ||||
![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 20 20"><rect fill="%23e5e7eb" width="20" height="20" rx="4"/></svg>){kind=small}
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialCulture Biosciences Competitors
Culture Biosciences competitors include listed companies like Abeja and Expert.ai, and private ones like SOM Biotech, Ripcord, Chooch and Sitetracker.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
 Barcelona | Private | - | - | $230M | - | |
| San Francisco, CA | Private | $23M | - | $250M | 10.9x | |
| San Francisco, CA | Private | - | - | $217M | - | |
| Montclair, NJ | Private | - | - | $186M | - | |
 Japan | Publicly listed | $23M | $3M | $208M | 6.4x | |
 Italy | Publicly listed | $53M | $5M | $203M | 4.3x |
Culture Biosciences Public Comps
Culture Biosciences is still privately-owned, but its public comps include Invivyd, SIGA Technologies, Protara Therapeutics, SmartRent, Protalix, Anavex Life Sciences, Guangzhou Innogen Pharma, REPLOID Group, Adagene and Eledon Pharmaceuticals.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $53M | ($50M) | 1.3x | 1.2x | (1.4x) | (0.6x) | |||
| $95M | $31M | 1.1x | 1.5x | 3.3x | 13.6x | |||
| - | ($63M) | - | - | (1.2x) | (0.9x) | |||
| $152M | ($56M) | 0.9x | 0.9x | (2.4x) | (54.1x) | |||
| $53M | ($4M) | 3.5x | 2.5x | (46.1x) | - | |||
| - | ($51M) | - | - | (2.1x) | - | |||
| $20M | ($50M) | 3.9x | 1.8x | (1.5x) | (2.3x) | |||
| $44M | $15M | 5.1x | - | 15.0x | - | |||
This data is available for Pro users. Sign up to see all Culture Biosciences competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Culture Biosciences
| When was Culture Biosciences founded? | Culture Biosciences was founded in 2016. |
| Where is Culture Biosciences headquartered? | Culture Biosciences is headquartered in San Francisco, CA, United States. |
| Is Culture Biosciences publicly listed? | No, Culture Biosciences is a private, VC-backed company. |
| What is Culture Biosciences' valuation? | Culture Biosciences was last valued at $220M in its Series B in October 2021. |
| How much funding has Culture Biosciences raised? | Culture Biosciences has raised $101M across 5 funding rounds. |
| What was Culture Biosciences' last funding round? | Culture Biosciences' last funding round was a Series C in December 2025, led by Cultivian Sandbox Ventures, Northpond Ventures, S32 and Synthesis Capital. |
| Who are Culture Biosciences' investors? | Culture Biosciences' investors include S32, Verily, Cultivian Sandbox Ventures, Northpond Ventures, E14 Fund, Synthesis Capital, Y Combinator, BoxGroup, The Production Board (TPB), Craft Ventures and 13 others. |
| Which companies are comparable to Culture Biosciences? | Companies comparable to Culture Biosciences include SOM Biotech, Ripcord, Chooch, Sitetracker, Abeja and Expert.ai. |
See companies similar to Culture Biosciences
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.